POE BRANDON, CFO, reported a transaction classified as exercise at BioStem Technologies, Inc. involving 10634.000000 shares for an estimated $0.00. Reported holdings after the transaction were 56368.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Financial Officer
These options vest according to the following schedule: 33% vested on August 11, 2026, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installmen…
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024).
These restricted stock units vest according to the following schedule: 33% vested on August 11, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two year peri…
These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarter…
0 other filings
0 recent txs